The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...

TAMPA, Fla. — The Food and Drug Administration has granted accelerated approval to the experimental drug lecanemab, shown to slow down the progression of Alzheimer’s disease in its early ...

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

A scan that can detect Alzheimer’s disease before memory loss begins is now available in the UAE for the first time. The amyloid PET scan, recently launched at Cleveland Clinic Abu Dhabi, is a ...